Flecainide Acetate NDC 42806-819

NDC codes

FDA NDC Directory

Product NDC (as listed)42806-819Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42806-0819Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42806-819-01	42806081901	100 TABLET in 1 BOTTLE (42806-819-01)Marketed from Sep 15, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Flecainide Acetate
Generic name (nonproprietary): flecainide acetate
Active ingredients: Flecainide acetate — 150 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Epic Pharma, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215599
Marketing start: Sep 15, 2022
Listing expires: Dec 31, 2027
Identifiers: Product ID 42806-819_52eef22b-3545-b398-e063-6394a90aec29SPL ID 52eef22b-3545-b398-e063-6394a90aec29SPL set ID 74c1eb2a-a37f-4f33-86bf-51e0d1d0c2bcRxCUI 886662, 886666, 886671UNII M8U465Q1WQUPC 0342806818015, 0342806817018, 0342806819012
Pharmacologic class: Antiarrhythmic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442806081901 followed by a unit qualifier and the quantity

Package 42806-0819-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 29, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Fle…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215599

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215599
Product	Strength	Form · route	Labeler	Product NDC
Flecainide Acetate	Flecainide acetate 100 mg/1	TabletOral	Bryant Ranch Prepack	71335-3063
Flecainide Acetate	Flecainide acetate 50 mg/1	TabletOral	Epic Pharma, LLC	42806-817
Flecainide Acetate	Flecainide acetate 100 mg/1	TabletOral	Epic Pharma, LLC	42806-818
Flecainide Acetate	Flecainide acetate 50 mg/1	TabletOral	Bryant Ranch Prepack	71335-2995
Flecainide Acetate	Flecainide acetate 150 mg/1	TabletOral	Bryant Ranch Prepack	71335-2523